Connect your AI

King Pharmaceuticals KG Equity Amortized Cost

Equity Amortized Cost at other companies

Universal Insurance HoldingsUVE

——

Other financials

Income statement

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

Operating cash flow-$15.1M-1,628%

Valuation

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

Net margin131.5%—

Returns & leverage

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's equity amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is King Pharmaceuticals's equity amortized cost?: King Pharmaceuticals (KG) reported equity amortized cost of $11.15M in Q1 2026.